UBS Group
APOPW

UBS Group’s Cellect Biotechnology Ltd. Warrants to Purchase ADRs APOPW Stock Holding History

UBS Group’s Portfolio APOPW Stock Details APOPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-62,507
Closed -$13K – 10752
2021
Q2 		$13K Buy
62,507
+59,659
+2,095% +$13.1K ﹤0.01% 7846
2021
Q1 		$1K Sell
2,848
-1,402
-33% -$450 ﹤0.01% 8894
2020
Q4 		$1K Buy
+4,250
New +$714 ﹤0.01% 8319
2017
Q4 		– Sell
-500
Closed -$1K – 8220
2017
Q3 		$1K Buy
+500
New +$1.1K ﹤0.01% 7617

UBS Group's APOPW Position: Q3 2021 in Review

UBS Group sold out of Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) in Q3 2021, closing a stake of 62,507 shares — an estimated $13K sold.

UBS Group first reported a position in APOPW in Q3 2017 and held it in 4 quarters. The position peaked at $13K in Q2 2021. 0 funds tracked by Wall St. Rank hold APOPW as of Q3 2021.

  • UBS Group reported no remaining Cellect Biotechnology Ltd. Warrants to Purchase ADRs position as of Q3 2021 after selling out during the quarter.
  • UBS Group sold 62,507 Cellect Biotechnology Ltd. Warrants to Purchase ADRs shares in Q3 2021, an estimated $13K.
  • UBS Group first reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in Q3 2017 and held it in 4 quarters.
  • UBS Group's Cellect Biotechnology Ltd. Warrants to Purchase ADRs position peaked at $13K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Cellect Biotechnology Ltd. Warrants to Purchase ADRs as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.